Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States

References

• Bell E, Brassel S, Oliver E, et al. Estimates of the global burden of COVID-19 and the value of broad and equitable access to COVID-19 vaccines. Vaccines. 2022;10(8):1320.
   Web of Science ®Google Scholar
• World Health Organization. WHO coronavirus (COVID-19) dashboard; 2022 [cited 2022 Dec 15]. Available from: https://covid19.who.int/table
   Google Scholar
• Centers for Disease Control and Prevention (CDC). CDC COVID data tracker [cited 2022 Dec 15]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
   Google Scholar
• Cutler DM, Summers LH. The COVID-19 pandemic and the $16 trillion virus. JAMA. 2020;324(15):1495–1496.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). CDC COVID data tracker: vaccination demographics trends; 2022 [cited 2022 Oct 30]. Available from: https://covid.cdc.gov/covid-data-tracker/
   Google Scholar
• Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022;71(45):1436–1441.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose; 2022 [cited 2022 Oct 30]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#:∼:text=The%20FDA%20amended%20the%20emergency,dose%20in%20younger%20age%20groups
   Google Scholar
• Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States; 2022 [cited 2022 Dec 15]. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
   Google Scholar
• Oliver S, editor. Evidence to recommendation framework: bivalent Covid-19 vaccine booster dose. ACIP meeting. CDC. Atlanta, Georgia; 2022.
   Google Scholar
• Bendix A. Covid booster shots: how to get updated vaccines targeting omicron subvariants (nbcnews.com). NBC News. 2022 [cited 2022 Oct 30]. Available from: https://www.nbcnews.com/health/health-news/covid-booster-shots-updated-target-omicron-ba4-ba5-rcna45893
   Google Scholar
• Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605–617.
   PubMed Web of Science ®Google Scholar
• Kirson N, Swallow E, Lu J, et al. The societal economic value of COVID-19 vaccines in the United States. J Med Econ. 2022;25(1):119–128.
   PubMed Web of Science ®Google Scholar
• Kohli M, Maschio M, Becker D, et al. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39(7):1157–1164.
   PubMed Web of Science ®Google Scholar
• Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. Int J Infect Dis. 2022;119:87–94.
   PubMed Web of Science ®Google Scholar
• Pandey A, Shah A, Moghadas SM, et al. How many lives could a Fall COVID-19 booster campaign save in the United States?; 2022 [cited 2022 Oct 30]. Available from: https://www.commonwealthfund.org/blog/2022/how-many-lives-could-fall-covid-19-booster-campaign-save-united-states
   Google Scholar
• The White House. Statement by President Biden on FDA and CDC authorizing updated COVID-19 vaccines. Washington (DC): The White House; 2022.
   Google Scholar
• Jarvis L. Covid boosters like flu shots, need a yearly schedule; 2022 [cited 2022 Oct 30]. Available from: https://www.bloomberg.com/opinion/articles/2022-06-01/covid-boosters-like-flu-shots-need-a-yearly-schedule?leadSource=uverify%20wall
   Google Scholar
• Centers for Disease Control and Prevention. Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity; 2021 [cited 2022 Oct 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html
   Google Scholar
• Leidner AJ, Chesson HW, Meltzer MI, et al. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices (ACIP); 2019 [updated 2019; cited 2022 Oct 30]. Available from: https://www.cdc.gov/vaccines/acip/committee/downloads/Economics-Guidance-for-ACIP-2019.pdf
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25(1):10–31.
   PubMed Web of Science ®Google Scholar
• US Census Bureau. National Population by Characteristics: 2010-2020; 2021 [cited 2022 Oct 30]. Available from: https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-national-detail.html
   Google Scholar
• Centers for Disease Control and Prevention. COVID-19 weekly cases and deaths per 100,000 population by age, race/ethnicity, and sex [cited 2022 Oct 30]. Available from: https://covid.cdc.gov/covid-data-tracker/#demographicsovertime
   Google Scholar
• Akinbami LJ, Kruszon-Moran D, Wang CY, et al. SARS-CoV-2 serology and self-reported infection among adults—national health and nutrition examination survey, United States, August 2021–May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1522–1525.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Reinfections and COVID-19; 2022 [cited 2022 Oct 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html
   Google Scholar
• Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 antibodies—United States, September 2021–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606–608.
   PubMed Web of Science ®Google Scholar
• Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open. 2022;5(8):e2225320.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. COVID reinfections surge during Omicron onslaught. Nature. 2022. DOI:10.1038/d41586-022-00438-3
   Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022;22(12):1663–1665.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron Sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respir Med. 2022;11(2):176–187.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimated COVID-19 burden; 2022 [cited 2022 October 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html
   Google Scholar
• Arbel R, Peretz A, Sergienko R, et al. Effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes: an observational cohort study. Lancet. 2023. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4314067
   PubMedGoogle Scholar
• Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to omicron BA.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults—increasing community access to testing program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119–124.
   PubMed Web of Science ®Google Scholar
• Surie D, Bonnell L, Adams K, et al. Effectiveness of monovalent mRNA vaccines against COVID-19–associated hospitalization among immunocompetent adults during BA.1/BA.2 and BA.4/BA.5 predominant periods of SARS-CoV-2 omicron variant in the United States—IVY network, 18 states, December 26, 2021–August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327–1334.
   PubMed Web of Science ®Google Scholar
• Surie D, DeCuir J, Zhu Y, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19 associated hospitalization among immunocompetent adults aged ≥65 years - IVY network, 18 states, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5152);1625–1630.
   PubMedGoogle Scholar
• Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-Associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults-VISION network, nine states, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5152):1616–1624.
   PubMedGoogle Scholar
• DeSilva MB, Mitchell PK, Klein NP, et al. Protection of 2 and 3 mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19 - VISION network, August 2021 - March 2022. J Infect Dis. 2022;jiac458.
   PubMed Web of Science ®Google Scholar
• Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422.
   PubMed Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(12):e2137257.
   PubMed Web of Science ®Google Scholar
• Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e192.
   PubMedGoogle Scholar
• Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624.
   PubMedGoogle Scholar
• Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci U S A. 2021;118(34):e210922918.
   Web of Science ®Google Scholar
• Thompson MG, Yoon SK, Naleway AL, et al. Association of mRNA vaccination with clinical and virologic features of COVID-19 among US essential and frontline workers. JAMA. 2022;328(15):1523–1533.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Laboratory-confirmed COVID-19-associated hospitalizations [cited 2022 Oct 30]. Available from: https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html
   Google Scholar
• Centers for Disease Control and Prevention. New admissions of patients with confirmed COVID-19, United States [cited 2022 Oct 30]. Available from: https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions
   Google Scholar
• Taylor CA, Whitaker M, Anglin O, et al. COVID-19–associated hospitalizations among adults during SARS-CoV-2 Delta and omicron variant predominance, by race/ethnicity and vaccination status—COVID-NET, 14 states, July 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):466–473.
   PubMed Web of Science ®Google Scholar
• Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308–317.
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Chinn J, Kirby K, et al. Outcomes of COVID-19 adults managed in an outpatient versus hospital setting. PLoS One. 2022;17(2):e0263813.
   PubMed Web of Science ®Google Scholar
• Bull-Otterson L, Baca S, Saydah S, et al. Post–COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years—United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713–717.
   Google Scholar
• Centers for Disease Control and Prevention. Long COVID or post-COVID conditions; 2022 [cited 2022 Oct 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
   Google Scholar
• O’Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762.
   PubMedGoogle Scholar
• Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804.
   PubMed Web of Science ®Google Scholar
• Chen C, Haupert SR, Zimmermann L, et al. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593–1607.
   PubMed Web of Science ®Google Scholar
• Funk AL, Kuppermann N, Florin TA, et al. Post-COVID-19 conditions among children 90 days after SARS-CoV-2 infection. JAMA Netw Open. 2022;5(7):e2223253.
   PubMed Web of Science ®Google Scholar
• Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695–1699.
   PubMed Web of Science ®Google Scholar
• DeMartino JK, Swallow E, Goldschmidt D, et al. Direct health care costs associated with COVID-19 in the United States. J Manag Care Spec Pharm. 2022;28(9):936–947.
   PubMed Web of Science ®Google Scholar
• Scott A, Chambers R, Reimbaeva M, et al. Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in the United States. J Med Econ. 2022;25(1):287–298.
   PubMed Web of Science ®Google Scholar
• FairHealth. COVID-19 medical and hospitalization costs: national; 2021 [cited 2022 Oct 30]. Available from: https://s3.amazonaws.com/media2.fairhealth.org/infographic/asset/COVID-19%20Medical%20Hospitalization%20Costs%20by%20State%20-%20FINAL_National.pdf
   Google Scholar
• Centers for Medicare and Medicaid Services. COVID-19 vaccines and monoclonal antibodies [cited 2022 Oct 30]. Available from: https://www.cms.gov/covid-19-vaccines-and-monoclonal-antibodies
   Google Scholar
• Pfizer Inc. Pharmaceuticals price list [data on file]. New York: Pfizer Inc.; 2023.
   Google Scholar
• Klein NP, Shimabukuro T. Safety update of 1st booster mRNA COVID-19 vaccination; 2022 [cited 2022 Oct 30]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-20/03-COVID-Klein-Shimabukuro-508.pdf
   Google Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021;325(8):780–781.
   PubMed Web of Science ®Google Scholar
• Healthcare Cost and Utilization Project. Free health care statistics [cited 2022 Oct 30]. Available from: https://hcupnet.ahrq.gov/#setup
   Google Scholar
• US Bureau of Labor Statistics. Labor force statistics from the current population survey; 2021 [cited 2022 Dec 13]. Available from: https://www.bls.gov/cps/cpsaat03.htm
   Google Scholar
• US Bureau of Labor Statistics. Table 3. Median usual weekly earnings of full-time wage and salary workers by age, race, Hispanic or Latino ethnicity, and sex, third quarter 2022 averages, not seasonally adjusted [cited 2022 Dec 13]. Available from: https://www.bls.gov/news.release/wkyeng.t03.htm
   Google Scholar
• Centers for Disease Control and Prevention. Ending isolation and precautions for people with COVID-19: interim guidance; 2022 [cited 2022 Dec 13]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
   Google Scholar
• Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232.
   PubMed Web of Science ®Google Scholar
• Kamdar BB, Huang M, Dinglas VD, et al. Joblessness and lost earnings after acute respiratory distress syndrome in a 1-year national multicenter study. Am J Respir Crit Care Med. 2017;196(8):1012–1020.
   PubMed Web of Science ®Google Scholar
• Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6.
   PubMedGoogle Scholar
• Di Fusco M, Sun X, Moran MM, et al. Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients. J Patient Rep Outcomes. 2022;6:123.
   PubMedGoogle Scholar
• Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med. 2000;109(8):614–620.
   PubMed Web of Science ®Google Scholar
• Nakshbandi G, Moor CC, Nossent EJ, et al. Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: the HOMECOMIN’ study. Respirology. 2022;27(7):501–509.
   PubMed Web of Science ®Google Scholar
• Sandmann F, Tessier E, Lacy J, et al. Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: longitudinal analysis and cross-sectional comparison with controls. Clin Infect Dis. 2022;75(1):e962–e973.
   Google Scholar
• van Hoek AJ, Underwood A, Jit M, et al. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One. 2011;6(3):e17030.
   PubMed Web of Science ®Google Scholar
• Sah P, Vilches TN, Moghadas SM, et al. Return on investment of the COVID-19 vaccination campaign in New York city. JAMA Netw Open. 2022;5(11):e2243127.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher MJ, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Di Fusco M, Mendes D, Steuten L, et al. The societal value of vaccines: expert-Based conceptual framework and methods using COVID-19 vaccines as a case study. Vaccines. 2023;11(2):234.
   Web of Science ®Google Scholar